Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Kiladjian on Ruxolitinib Plus Interferon in MPNs

February 27th 2019

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses a study of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasms.

Dr. Kambhampati Discusses Role of Interferon in MPNs

February 26th 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

Subcutaneous Daratumumab Succeeds in Phase III Myeloma Trial

February 26th 2019

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

Iomab-B Shows Promise as Novel Conditioning for HSCT in AML

February 25th 2019

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

Dr. Lulla Discusses Post-Transplant Options for Leukemias

February 24th 2019

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Thrombotic Microangiopathy a Threat After Hematopoietic Cell Transplant

February 23rd 2019

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22nd 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Pretransplant MRD Prognostic for Outcomes in Adults With ALL

February 22nd 2019

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Expert Discusses Evolution, Impact of Interferon in MPNs

February 21st 2019

Srdan Verstovsek, MD, PhD, discusses the use of interferon in rare blood diseases.

Dr. Kambhampati on Challenges in CLL

February 21st 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

FDA Grants Ivosidenib Priority Review for Frontline IDH1+ AML

February 21st 2019

The FDA has granted a priority review to a supplemental new drug application for ivosidenib for the frontline treatment of patients IDH1-mutant acute myeloid leukemia who are ineligible for standard chemotherapy.

Mesa Explores Role of Interferon in Evolving MPN Treatment Paradigm

February 20th 2019

Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.

FDA Grants Polatuzumab Vedotin Priority Review for DLBCL

February 19th 2019

The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Consistent Findings Validate Viability of TKI Discontinuation in CML

February 14th 2019

First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.

Novel AML Strategies Aim to Restore Regulatory Gene Functions

February 14th 2019

Acute promyelocytic leukemia, a rare genetic subtype of de novo acute myeloid leukemia is treated not with conventional cytotoxic chemotherapy but with just 2 drugs: all-trans retinoic acid and arsenic trioxide. Given this, an enduring question has been whether noncytotoxic differentiation-restoring therapy can be extended to the most common genetic subtypes of AML.

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies

February 13th 2019

New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

Brentuximab Vedotin Approved in Europe for Frontline CD30+ Hodgkin Lymphoma

February 12th 2019

The European Commission has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.

Talley Talks Treatment Strategies in ITP and TTP

February 11th 2019

Robert L. Talley, MD, discusses current and potential future standards of care in idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.

Dasatinib Approved in EU for Pediatric Ph+ ALL

February 11th 2019

The European Commission has approved dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

FDA Extends Review Period for Ruxolitinib in GVHD

February 8th 2019

The FDA has added 3 months to the review period for a supplemental new drug application for ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids, making the new action date May 24, 2019.